Brainstorm cell therapeutics announces agreement with fda on a special protocol assessment (spa) for phase 3b trial in als

Conference call and webcast at 8:00 a.m. eastern time today new york , april 9, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the u.s. food and drug administration (fda), under a special protocol assessment (spa), on the design for a phase 3b trial of nurown® in amyotrophic lateral sclerosis (als).
BCLI Ratings Summary
BCLI Quant Ranking